**Preface to "New Insights into Endometrial Cancer 2022"**

Endometrial cancer is a hormone-dependent cancer with an increasing incidence that is estimated to continue to grow over the next several years. It is typically treated with surgery and/or chemo-/radiation therapy. The clinical benefit of hormone therapies for advanced and recurrent endometrial cancers underlines the need to examine their characteristics (particularly, steroid hormone receptor expression and functions) to assess how they can be used better. Furthermore, a critical phase that can drive clinicians' therapeutic choices is histopathological and molecular classification. Thus, a current challenge is to integrate IHC markers with molecular tests to identify prognostic groups. Moreover, the observations of the immunosuppressive nature of the endometrial cancer environment are leading to studies that assess therapies with the aim to boost the immune response, which might represent significant potential in the treatment of the disease. For this reason, current and ongoing studies are trying to improve clinical responses through immunotherapy strategies, either alone or combined with classic treatments.

> **Laura Paleari** *Editor*
